Curated News
By: NewsRamp Editorial Staff
June 17, 2026

BioElectronics and Electrome Launch AI-Powered Pain Relief Campaign

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • BioElectronics and Electrome launch AI-driven campaign for FDA-cleared ActiPatch, gaining first-mover advantage in non-pharmaceutical pain relief.
  • Electrome builds AI-native platform integrating predictive analytics and ecommerce to scale BioElectronics' drug-free pulsed shortwave therapy.
  • Drug-free pain relief technology becomes accessible to millions, reducing reliance on opioids and improving quality of life.
  • Wearable device uses pulsed shortwave therapy to relieve pain without drugs, cleared by FDA for home use.

Impact - Why it Matters

This news matters because it signals a major shift toward drug-free pain management solutions, leveraging AI and digital marketing to make FDA-cleared, non-invasive therapies widely accessible. For consumers suffering from chronic pain, this could offer an effective alternative to opioids and other drugs, reducing side effects and addiction risks. The partnership also highlights the growing role of AI in healthcare commercialization, potentially setting a new standard for how medical devices are marketed and adopted.

Summary

BioElectronics Corporation (OTC: BIEL) has announced that its strategic distribution and licensing agreement with Electrome Corporation has officially entered the execution phase, with manufacturing now underway for the launch of its flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform. The partnership aims to accelerate awareness and adoption of BioElectronics’ FDA-cleared, drug-free pain relief technologies across North America. Key players include Kelly Whelan, President of BioElectronics, and Ken Mayer, CEO of Electrome. Electrome is building a comprehensive AI-native pain management platform that integrates artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. Under the agreement, Electrome will market and distribute BioElectronics’ products, including ActiPatch and other portfolio items. The initial purchase order has been received, and manufacturing is underway for a consumer launch campaign. Electrome’s strategy focuses on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems. BioElectronics’ technology uses pulsed shortwave therapy for non-invasive, drug-free pain relief, cleared by the FDA for musculoskeletal pain. The technology has been studied in multiple clinical applications and is designed for home use. Manufacturing activities are progressing, with commercial launch preparations covering branding, ecommerce, logistics, customer support, and digital marketing. For more details, visit the original release on NEWMEDIAWIRE.

This partnership marks a significant milestone, as Electrome prepares an aggressive consumer launch strategy leveraging AI-driven technologies. The companies believe this positions them for significant growth in the non-pharmaceutical pain management market. BioElectronics Corporation is a medical device company focused on bioelectronic therapies, while Electrome Corporation is a technology-enabled healthcare commercialization company using AI and digital marketing to scale healthcare products in the direct-to-consumer marketplace.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioElectronics and Electrome Launch AI-Powered Pain Relief Campaign

blockchain registration record for this content.